PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.1% Following Analyst Upgrade
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shot up 6.1% during trading on Monday after Cantor Fitzgerald raised their price target on the stock from $76.00 to $113.00. Cantor Fitzgerald currently has an overweight rating on the stock.
StockStory.org on MSN20h
PTC Earnings: What To Look For From PTCEngineering and design software provider PTC (NASDAQ:PTC) will be reporting earnings tomorrow afternoon. Here’s what to ...
Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating ...
Wall Street analysts expect PTC Inc. (PTC) to post quarterly earnings of $0.91 per share in its upcoming report, which indicates a year-over-year decline of 18%. Revenues are expected to be $551.92 ...
Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...
Check the time stamp on this data. Updated AI-Generated Signals for Ptc Inc. (PTC) available here: PTC. Type a few symbols ...
The U.S. Department of the Treasury and IRS on Jan. 10, 2025, released initial guidance regarding the production tax credit (PTC) for clean ...
Loop Capital Markets analyst Yun Kim maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $240.00. The ...
周一，Cantor Fitzgerald的分析师对PTC Therapeutics (NASDAQ: PTCT )表现出积极看法，将目标价从之前的76.00美元上调至113.00美元。该公司维持对该股票的超配评级。根据 InvestingPro 数据，该股票在过去一年中实现了82%的回报率，分析师目标价范围从32美元到76美元不等。此次上调伴随着对公司财务状况和前景的详细分析。
PTC PTC underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback